Get started
Author

Sebastian Marcel Wingen-Heimann

Observed names: S.M. Wingen-Heimann, Sebastian M. Wingen-Heimann, Sebastian M. Wingen‐Heimann, Sebastian Wingen-Heimann, Sebastian Wingen‐Heimann, Wingen-Heimann, Sebastian, Wingen-Heimann, Sebastian M., Wingen-Heimann, Sebastian Marcel
Observed institutions: TH Köln - University of Applied Sciences, Hochschule Bremen, University of Cologne, FOM University of Applied Sciences for Economics and Management, German Center for Infection Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Bundeswehrzentralkrankenhaus Koblenz
ORCID: 0000-0002-4232-6944
Observed ORCID: 0000-0002-4232-6944
OpenAlex ID: A5084457251
Attributable mortality of candidemia after introduction of echinocandins
2020 · Florian B. Cornely, Oliver A. Cornely, et al. · Mycoses · 54
PDF
Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)
2022 · Sebastian M. Wingen-Heimann, Sebastian M. Wingen-Heimann, et al. · Clinical Microbiology and Infection · 43
PDF
Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients
2022 · Michelle Gerards, Ann-Katrin Schild, et al. · Dementia and Geriatric Cognitive Disorders · 29
PDF
Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
2024 · Sina M. Pütz, Sebastian M. Wingen-Heimann, et al. · Journal of Infection · 22
PDF
Facilitators and barriers for the implementation of resuscitation training programmes for schoolchildren
2021 · Sabine Wingen, Julia Jeck, et al. · European Journal of Anaesthesiology · 13
Staphylococcus aureus surgical site infection rates in 5 European countries
2023 · Sibylle C. Mellinghoff, Caroline Bruns, et al. · Antimicrobial Resistance and Infection Control · 12
PDF
Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States
2025 · Ilana Reinhold, Giovanni Mori, et al. · Mycoses · 9
PDF
Antimicrobial susceptibility in Clostridioides difficile varies according to European region and isolate source
2024 · Jane Freeman, Virginie Viprey, et al. · JAC-Antimicrobial Resistance · 9
Impact of testing on Clostridioides difficile infection in hospitals across Europe: a mathematical model
2023 · Emily Agnew, Kerrie A. Davies, et al. · Clinical Microbiology and Infection · 9
PDF
Principal‐agent theory‐based cost and reimbursement structures of isavuconazole treatment in German hospitals
2020 · Florian Kron, Sebastian M. Wingen‐Heimann, et al. · Mycoses · 8
PDF
The economic burden ofClostridioides difficileinfection in patients with hematological malignancies in the United States: A case-control study
2020 · Lola Duhalde, Lise Lurienne, et al. · Infection Control and Hospital Epidemiology · 7
Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the USA
2019 · L. Duhalde, L. Lurienne, et al. · Journal of Hospital Infection · 7
Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany
2022 · Julia Jeck, Sebastian M. Wingen-Heimann, et al. · Healthcare · 6
PDF
The need for a holistic view on management of Clostridioides difficile infection
2021 · Sebastian M. Wingen-Heimann, Joffrey van Prehn, et al. · Clinical Microbiology and Infection · 6
PDF
Costs and resource utilization patterns in surgical site infections: a pre-COVID-19 perspective from France, Germany, Spain, and the UK
2024 · J. Salmanton-García, C. Bruns, et al. · Journal of Hospital Infection · 5
PDF
Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin – A real-world data and retrospective cost analysis
2023 · Christoph T. Baltin, Carolin Wulf, et al. · Journal of Infection and Public Health · 5
Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six‐year cohort analysis
2020 · Sebastian M. Wingen‐Heimann, Oliver A. Cornely, et al. · Mycoses · 4
PDF
Clinical and health economic impact of isavuconazole for treatment of invasive aspergillosis and mucormycosis: a retrospective, matched multicentre cohort study in Germany
2025 · Marie Engelhard, Sebastian M. Wingen-Heimann, et al. · Infection · 3
PDF
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
2021 · Florian Jakobs, Sebastian Marcel Wingen-Heimann, et al. · BMC Health Services Research · 3
PDF
Health economic burden of refractory and recurrent Clostridioides difficile infection in the inpatient setting of the German healthcare system – the IBIS Study
2025 · S.M. Wingen-Heimann, A. Ullah, et al. · Journal of Hospital Infection · 2
PDF
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre
2023 · Julia Jeck, Sebastian M. Wingen‐Heimann, et al. · Mycoses · 2
PDF
Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole
2021 · Julia Jeck, Sebastian M. Wingen‐Heimann, et al. · Mycoses · 2
PDF
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
2026 · Isabella Alram, Sebastian M. Wingen-Heimann, et al. · BMC Infectious Diseases · 1
Evaluating the health economic impact of cefepime/enmetazobactam in complicated urinary tract infections in the German setting: a cost analysis from payer perspective
2025 · Johanna Röder, Sebastian M. Wingen-Heimann, et al. · Infection · 1
PDF
Epidemiology and Course of Clostridioides difficile Infections in Germany: Retrospective Analysis of German Health Claims Data
2025 · Anna Seiffert, Sebastian Noack, et al. · Infectious Diseases and Therapy · 1
PDF
Works count: 46
Citation count: 268
H-index: 9
I10-index: 6
Year
Topic
Type